TOP >
News Release
> list in 2008
- 2008.12.19
- Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
- 2008.12.19
-
Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japan’s Daiichi Sankyo
Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board
- 2008.12.19
- Announcement regarding ActHib®(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b) launch
- 2008.12.11
- Daiichi Sankyo Submits Application for Approval of CS-866AZ Antihypertensive Combination Drug in Japan
- 2008.12.08
- NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
- 2008.11.17
- DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.11.13
- DAIICHI SANKYO EUROPE GmbH announce SEVIKAR® a new fixed dose combination treatment for essential hypertension
- 2008.11.13
- Daiichi Sankyo's Research Foundation Establishes First Annual Clinical Pharmacology Research Award
- 2008.11.11
-
ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
Product development agreement focused on ARQ 197, c-Met inhibitor,with discovery collaboration directed toward novel kinase inhibitors;
- 2008.11.10
- Announcement regarding ActHib(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)launch date
- 2008.10.31
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.10.20
-
Daiichi Sankyo and Ranbaxy Move Forward Toward
The Completion of the Landmark Deal
- 2008.10.17
-
Daiichi Sankyo and Lilly Respond to Speculation
On Status of Prasugrel New Drug Application
- 2008.09.30
- Announcement regarding ActHib(R)(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)
- 2008.09.02
-
Daiichi Sankyo Announces Clinical Study Data for
Oral Factor Xa Inhibitor DU-176b
- 2008.08.25
- Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
- 2008.07.17
- Daiichi Sankyo and Ranbaxy confirm Deal is Binding and Final Allay market rumour and speculation
- 2008.07.16
- Asubio Pharma’s Inherited Metabolic Disease Agent Biopten®Receives Approval for Additional Indication
- 2008.07.16
- Approval Acquired for Additional Indication for the Selective Antithrombin Agents Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL For the Inhibition of Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Type II
- 2008.07.09
- Percutaneous Absorption-type Analgesic and Anti-Inflammatory Drug Loxonin(R) Tape 50mg/100mg Launched
- 2008.07.09
-
Luitpold Pharmaceuticals/American Regent and Fresenius Medical Care sign
agreements for exclusive sublicense of Venofer(R)in U.S.
- 2008.06.24
-
FDA Extends Review Period for Daiichi Sankyo, Lilly
Investigative Antiplatelet Drug, Prasugrel
- 2008.06.18
- New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
- 2008.06.11
-
Ranbaxy to bring in Daiichi Sankyo as Majority Partner
Strategic Combination creates Innovator and Generic Pharma Powerhouse
- 2008.06.05
-
DAIICHI SANKYO COMMENCES PATENT LITIGATION AGAINST MYLAN
AND MATRIX IN THE UNITED STATES
- 2008.06.02
-
Broad-spectrum Oral Antibacterial Agent
Gracevit(R) Tablets 50mg/Fine Granules 10% Launched
- 2008.06.02
-
DAIICHI SANKYO Contributes to Relief Efforts for
Cyclone Nargis and Sichuan Earthquake Victims
- 2008.05.13
-
FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE
THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT
- 2008.04.16
- Welchol(R) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus"
- 2008.03.31
- Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
- 2008.03.12
-
The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
Receives Approval for Manufacture and Marketing
- 2008.03.12
-
Luitpold Pharmaceutical's INJECTAFER(TM)
(ferric carboxymaltose injection) receives non-approvable letter from FDA
- 2008.03.05
-
Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
DAIICHI SANKYO presses ahead with European expansion
- 2008.02.22
-
FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention
- 2008.02.20
-
Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
Investigational Oral Antiplatelet Drug, Prasugrel, to European
Medicines Agency
- 2008.02.15
-
DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
(Stock Acquisition Rights) as Remuneration
- 2008.02.04
- FDA Advisory Committee Supports Favorable Risk-Benefit Profile for Injectafer(TM)(Ferric Carboxymaltose Injection) Under Certain Indications for Use
- 2008.02.01
- Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
- 2008.01.28
-
Broad-spectrum Oral Antibacterial Agent
Gracevit(R) tablets 50mg/fine granules 10%
Receives Approval for Manufacturing and Marketing
- 2008.01.21
- Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
